Developments in the Systemic Treatment of Endometrial Cancer
Developments in Treatment of Endometrial Cancer
G Mountzios, D Pectasides, E Bournakis, E Pectasides, G Bozas, MA Dimopoulos, CA Papadimitriou
Yes
20110801
2011 Sept 1
Crit Rev Oncol Hematol
Developments in the Systemic Treatment of Endometrial Cancer
Crit Rev Oncol Hematol. 2011 Sept 1;79(3):278-292, G Mountzios, D Pectasides, E Bournakis, E Pectasides, G Bozas, MA Dimopoulos, CA Papadimitriou
Abstract
Abstract
Systemic treatment represents the cornerstone of endometrial cancer management in advanced, relapsed and metastatic disease, which is still characterized by poor prognosis. Progestins remain an effective option for patients with low grade, estrogen and/or progesterone receptor positive disease, with some of them achieving prolonged survival. Platinum compounds, anthracyclines and more recently taxanes have been implemented in combination regimens achieving response rates more than 50% and resulting...
